VERAXA Biotech Advances Lead BiTAC® T-Cell Engager Program with Cell Line Development Partnership

VERAXA Biotech (VRXA) Advances Lead BiTAC® T-Cell Engager Program With Cell Line Development Partnership

LOS ANGELES, CA - July 9, 2026 (NEWMEDIAWIRE) - VERAXA Biotech (NASDAQ: VRXA), an emerging leader in designing novel cancer therapies, has begun cell line development for its lead BiTAC(R) T-cell engager (“BiTAC(R)-TCE”) program, marking another step in preparing the company’s most advanced oncology candidate for future clinical development. The company has initiated cell line development for its lead BiTAC(R) T-cell engager program, selecting …

VERAXA Biotech Advances Lead BiTAC® T-Cell Engager Program with Cell Line Development Partnership

VERAXA Biotech (NASDAQ: VRXA) has taken a significant step forward in its lead BiTAC® T-cell engager program by initiating cell line development, moving the oncology candidate closer to clinical trials. The company announced it has selected ATUM, a U.S.-based contract research organization specializing in bioengineering and cell line development, to generate stable clonal cell lines using its proprietary Leap-In Transposase® technology. This col…